share_log

Benchmark Maintains Speculative Buy on ImmunoPrecise Antibodies, Lowers Price Target to $7

Benchmark Maintains Speculative Buy on ImmunoPrecise Antibodies, Lowers Price Target to $7

Benchmark 维持对免疫精准抗体的投机性买入,将目标价下调至7美元
Benzinga ·  2023/03/21 12:32

Benchmark analyst Robert Wasserman maintains ImmunoPrecise Antibodies (NASDAQ:IPA) with a Speculative Buy and lowers the price target from $12 to $7.

基准分析师罗伯特·沃瑟曼维持免疫精准抗体(纳斯达克:IPA)的投机性买入,并将目标价从12美元下调至7美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发